Funding Received
$44.8 Million in 4 Rounds from 2 Investors
Most Recent Funding
$17 Million Series D on March 25, 2014
Headquarters:
Cambridge, MA
Description:
NeuroPhage develops disease-modifying therapies for Alzheimer’s, Parkinson’s, Huntington’s, ALS, MS and other neurodegenerative diseases.
Categories:
Biotechnology
Website:
http://www.neurophage.com

Company Details

Update
Founded:
2006
Contact:
Employees:
7 in CrunchBase

NeuroPhage Pharmaceuticals, Inc., a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. It offers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Funding Rounds (4) - $44.8M

Update

Investors (2)

Update

Offices/Locations (1)

Update
  • Office

    222 Third Street

    Suite 3120

    Cambridge, MA 02142

    USA

Images (1)

Update
  • Fd5c49311c3f41ccbc3412e2f38cb347